Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Jean-Charles Crave"'
Publikováno v:
Case Reports in Neurology, Vol 7, Iss 3, Pp 227-232 (2015)
Introduction: Inclusion body myositis (IBM) is a slowly progressive degenerative inflammatory disorder affecting both proximal and distal muscles. Immunosuppressive therapies are generally ineffective in the treatment of this disorder, and most patie
Externí odkaz:
https://doaj.org/article/ea35195e077747a2a082a8bcdc057859
Publikováno v:
Case Reports in Rheumatology, Vol 2015 (2015)
Externí odkaz:
https://doaj.org/article/b1b75229e7134c97acf8b1309d970640
Autor:
Taylor Pindi Sala, MD, PhD, Daniel Matondo Masisa, MD, MPH, Jean Charles Crave, MD, PhD, Chafke Belmokhtar, PhD, Guillaume LeNy, PhamD, Hippolyte Situakibanza, MD, PhD, Martin Duracinsky, MD, PhD, Patrick Cherin, MD, PhD, Olivier Chassany, MD, PhD
Publikováno v:
Journal of Allergy and Clinical Immunology: Global, Vol 3, Iss 1, Pp 100173- (2024)
Background: Long-term therapeutic adherence remains an essential challenge for better management of chronic diseases. It is estimated at 50% in developed countries. Objective: The study aimed to evaluate, under real conditions, the influence of satis
Externí odkaz:
https://doaj.org/article/97cd8f91c8f14fe3b968412a360718d7
Autor:
Mona Villedieu, Ljudmila Stojanovich, Cristina Belizna, Vivien Pautot, Jean-Charles Crave, Laura Damian, Patrick Cherin, Jan Willem Cohen Tervaert, Taylor Pindi Sala
Publikováno v:
Journal of Neurology. 267:3499-3507
The most common peripheral nervous system manifestations in Sjogren's syndrome are small fiber sensory neuropathies (SFPN) and axonal sensorimotor polyneuropathies. Currently, treatment in small fiber neuropathy is mainly symptomatic and based on ant
Autor:
Jean-Charles Crave, Martin Duracinsky, Patrick Cherin, Taylor Pindi Sala, Pierre Clerson, Olivier Chassany, Annaïk Dokhan, Yann Fardini
Publikováno v:
Medicine
Medicine, Lippincott, Williams & Wilkins, 2020, 99 (7), pp.e19012. ⟨10.1097/MD.0000000000019012⟩
Medicine, Lippincott, Williams & Wilkins, 2020, 99 (7), pp.e19012. ⟨10.1097/MD.0000000000019012⟩
Supplemental Digital Content is available in the text
Immunoglobulins are 2nd or 3rd-line treatments in dermatomyositis (DM) or polymyositis (PM) refractory to high-dose corticosteroids and immunosuppressants. Immunoglobulins (2 g/kg/mo) are usu
Immunoglobulins are 2nd or 3rd-line treatments in dermatomyositis (DM) or polymyositis (PM) refractory to high-dose corticosteroids and immunosuppressants. Immunoglobulins (2 g/kg/mo) are usu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d05acf6ccf703ce16695162767202ac
https://hal.sorbonne-universite.fr/hal-02555777/file/Recovering_autonomy_is_a_key_advantage_of.22.pdf
https://hal.sorbonne-universite.fr/hal-02555777/file/Recovering_autonomy_is_a_key_advantage_of.22.pdf
Autor:
Vincent Levy, Jean-Charles Crave, Bruno Royer, Jean-François Viallard, Olivier Decaux, Frédéric Bauduer, Pierre Clerson, Sylvain Choquet, Yann Fardini, Omar Benbrahim
Publikováno v:
European Journal of Haematology. 101:48-56
Objective To describe the characteristics of patients suffering from secondary immunodeficiencies (SID) associated with hematological malignancies (HM), who started immunoglobulin replacement therapy (IgRT), physicians' expectations regarding IgRT, a
Autor:
Sylvie Brice, Dominique Lachaud, Anne-Laure Fauchais, Pierre Miossec, Jean-Charles Crave, Pierre Clerson, Grégoire Cozon, Françoise Renon-Carron, Jean-François Viallard, Cyrille Hoarau, Yann Fardini, Boris Bienvenu, Daniel Antier, Yves Mataix, Eric Hachulla, Antoine Alix, Stéphanie Tamisier
Publikováno v:
Journal of Clinical Immunology
Purpose Subcutaneous immunoglobulin replacement therapy (IgRT) may be administered once a week with a pump or every other day with a syringe (rapid push). The objective of the study was to compare the impact of pump and rapid push infusions on patien
Autor:
Taylor Pindi Sala, Annaïck Dokhan, Grégoire Cozon, Jean-Charles Crave, Pierre Clerson, Yann Fardini
Publikováno v:
Patient preference and adherence
Grégoire Jacques Noël Cozon,1 Pierre Clerson,2 Annaïk Dokhan,3 Yann Fardini,2 Taylor Pindi Sala,4 Jean-Charles Crave4 1Department of Clinical Immunology and Rheumatology, Edouard Herriot Hospital, Lyon, France; 2Soladis Clinical Studies, Roubaix,
Autor:
Jean-Charles Crave, Sylvain Choquet, Yann Fardini, Bruno Royer, Frédéric Bauduer, Omar Benbrahim, Jean-François Viallard, Vincent Levy, Pierre Clerson, Olivier Decaux
Publikováno v:
Hematology (Amsterdam, Netherlands). 24(1)
Immunoglobulin replacement therapy (IgRT) is increasingly used in secondary immunodeficiency (SID) related to hematological malignancies (HM) to prevent infections. Study's objective was to document prospectively the efficacy and safety of IgRT in pa
Autor:
Georgeta Lascu-Dubos, Patrick Cherin, Christophe de Jaeger, Cristina Belizna, Jean-Christophe Delain, Eric Hachulla, Jean-Charles Crave, Odile Cartry
Publikováno v:
Autoimmunity Reviews. 15:281-286
Subcutaneous immunoglobulin (SCIg) therapy is indicated in primary and secondary immunodeficiency diseases. Its use in practice is being extended to autoimmune diseases. Few studies investigated the feasibility and safety of SCIg in these rare condit